28.2 C
Vientiane
Monday, June 30, 2025
spot_img
Home Blog Page 716

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®

  • STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1], [2]
  • The FDA approval is based on robust clinical evidence, which show no clinically meaningful differences from the reference products
  • With the FDA approval of STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) Celltrion’s biosimilar portfolio continues to grow, expanding treatment options to reach more patients

JERSEY CITY, N.J., March 4, 2025 /PRNewswire/ — Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively for all indications of reference products.[1], [2]

“The approval of STOBOCLO and OSENVELT is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture as well as cancer-related skeletal events,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “Patients deserve therapeutic options that have the potential to make real impacts on their care and their lives. We are committed to continuous innovation to meet these goals leveraging our experience and successful track record with biosimilar and novel biologics.”

The FDA approval is based on robust clinical evidence, including results from Phase III clinical trials in postmenopausal women with osteoporosis designed to evaluate the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), safety and immunogenicity of CT-P41 to reference denosumab. Study results demonstrated that CT-P41 had equivalent efficacy and PD to reference denosumab with similar PK and comparable safety and immunogenicity profiles.

“Denosumab is used to improve or protect bone health in patients with osteoporosis or those undergoing various cancer treatments and as a therapy for a lifetime for postmenopausal osteoporosis (PMO) patients,” said Prof. Jean-Yves Reginster, Professor of Medicine, Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia and Director WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging, Liège, Belgium. “Biosimilars have expanded into new therapeutic areas such as immunology, oncology and ophthalmology as they continue to offer significant cost-saving potential while expanding patient access. Having a denosumab product with a clinically proven track record in quality and safety is a valuable addition for my patients.”

In accordance with a settlement agreement with Amgen Inc., STOBOCLO and OSENVELT are expected to be available in the U.S. in June 2025.

About STOBOCLO® (denosumab-bmwo) 

STOBOCLO® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing PROLIA® (denosumab). STOBOCLO 60 mg/mL injection is approved by the FDA based on comprehensive data and clinical evidence confirming the therapeutic equivalence to PROLIA. In the U.S., STOBOCLO is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. STOBOCLO was also approved by the European Medicines Agency (EMA) in February 2025.

INDICATIONS

STOBOCLO® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for treatment:

  • of postmenopausal women with osteoporosis at high risk for fracture
  • to increase bone mass in men with osteoporosis at high risk for fracture or in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
  • to increase bone mass in women at high risk for fracture receiving a adjuvant aromatase inhibitor therapy for breast cancer

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE

Patients with advanced chronic kidney disease, including those on dialysis, face a higher risk of severe hypocalcemia after denosumab administration, with reported cases leading to hospitalization, life-threatening events, and fatalities.

The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients

Before starting STOBOCLO® (denosumab-bmwo) in advanced chronic kidney disease patients, assess for CKD-MBD. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD.

STOBOCLO is contraindicated in hypocalcemia, pregnant women, and in patients with known hypersensitivity to denosumab.

Severe Hypocalcemia: Ensure adequate calcium and vitamin D; monitor for severe hypocalcemia.

Drug Products with Same Active Ingredient: Do not use with other denosumab products.

Hypersensitivity: If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of STOBOCLO.

Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on STOBOCLO. Conduct oral exams before treatment; maintain oral hygiene; consider discontinuation of STOBOCLO if ONJ develops.

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of STOBOCLO therapy should be considered, pending a benefit-risk assessment, on an individual basis.

Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO.

Serious Infections: Higher risk in denosumab users; assess benefit-risk profile, especially in immunocompromised patients. Assess the benefit-risk profile before starting STOBOCLO and reconsider its use if serious infections develop.

Dermatologic Adverse Reactions: Consider discontinuing STOBOCLO if severe dermatitis, eczema, or rashes occur.

Musculoskeletal Pain: Consider discontinuation of STOBOCLO if severe pain develops.

Bone Turnover Suppression: In clinical trials in women with postmenopausal osteoporosis, denosumab significantly suppressed bone remodelling; patients should be monitored for these outcomes.

Hypercalcemia in Pediatrics Patients with Osteogenesis Imperfecta: Not for pediatric use; hypercalcemia reported in patients osteogenesis imperfecta treated with denosumab products.

Most common Adverse Reactions:

  • In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. Male osteoporosis were back pain, arthralgia, and nasopharyngitis.
  • Glucocorticoid-induced osteoporosis (> 3%) were back pain, hypertension, bronchitis, and headache.
  • Bone loss due to hormone ablation for cancer (≥ 10%) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials.

For more information, see Full Prescribing Information.

About OSENVELT® (denosumab-bmwo) 

OSENVELT® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing XGEVA® (denosumab). OSENVELT 120 mg/1.7 mL (70 mg/mL) injection is approved by the FDA based on a robust clinical trial and comprehensive data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. OSENVELT was also approved by the European Medicines Agency (EMA) in February 2025.

INDICATION

OSENVELT® (denosumab-bmwo) is indicated for:

  • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
  • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

IMPORTANT SAFETY INFORMATION

Contraindications: Patients with hypocalcemia or with known clinically significant hypersensitivity to denosumab products.

Drug Products with Same Active Ingredient. Patients receiving OSENVELT should not receive other denosumab products concomitantly.

Hypersensitivity. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of OSENVELT.

Hypocalcemia. Severe hypocalcemia can occur, and fatal cases have been reported. Monitor calcium levels and calcium and vitamin D intake.

Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on OSENVELT. Conduct oral exams and appropriate preventive dentistry before and during treatment; maintain oral hygiene and avoid invasive dental procedures; consider discontinuation of OSENVELT if ONJ develops.

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of OSENVELT therapy should be considered, pending a benefit-risk assessment, on an individual basis.

Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons. Clinically significant hypercalcemia, potentially requiring hospitalization, can occur within a year after stopping denosumab in patients with giant cell tumor of bone or growing skeletons; monitor serum calcium and manage calcium and vitamin D needs post-discontinuation.

Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation. Increased risk post-discontinuation of denosumab; evaluate for risk for vertebral fractures after discontinuing OSENVELT.

Embryo-Fetal Toxicity. Denosumab may cause fetal harm; verify pregnancy status before starting OSENVELT and advise effective contraception during treatment and for 5 months after the last dose.

Most common Adverse Reactions:

  • Bone Metastasis from Solid Tumors (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea.
  • In patients (≥ 10%) with: Multiple Myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache; Giant Cell Tumor of Bone were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity.
  • Hypercalcemia of Malignancy (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media – LinkedInInstagramX, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has seven biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), STEQEYMA® (Ustekinumab-stba), and AVTOZMA® (tocilizumab-anoh) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media – LinkedIn

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

STOBOCLO® and OSENVELT® are registered trademarks of Celltrion Inc.
PROLIA® and XGEVA® are registered trademarks of Amgen Inc.

References

[1] STOBOCLO U.S. prescribing information (2024)

[2] OSENVELT U.S. prescribing information (2024)

US-CT-P41-24-00010

For further information please contact: 
Andria Arena
aarena@jpa.com
+1 516-578-0057

Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility

BANGKOK, March 4, 2025 /PRNewswire/ — Chulalongkorn University has introduced the Exoskeleton Wheelchair, an innovative robotic suit designed to help people with disabilities stand, walk, and move more independently. The breakthrough was developed by Assoc. Prof. Dr. Ronnapee Chaichaowarat from the Faculty of Engineering, aiming to improve mobility beyond traditional wheelchairs.

Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility
Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility

A New Frontier in Robotics

The robotics lab at Chulalongkorn University, located on the 9th floor of Chulapat-14 Building, serves as a hub for students and researchers from Thailand and abroad to collaborate on cutting-edge robotics projects. Dr. Ronnapee envisioned this lab as an alternative learning space, where students build and test robots through hands-on experimentation.

The World’s First Thai-Made Exoskeleton Wheelchair

Nicknamed “Thai Iron Man,” this innovation is the first exoskeleton wheelchair built by Thai researchers. Unlike conventional wheelchairs, it can transform to help users stand and walk, making it easier to navigate stairs or public transport. The project received funding from Thailand’s National Research Council (NRCT) in 2021–2022 and was a finalist in the 2024 Young Technologists Award.

How It Works

The Exoskeleton Wheelchair is a wearable robotic device that supports users by combining a wheelchair and exoskeleton into a hybrid system. Made with lightweight carbon fiber, and equipped with foldable wheels, the robot allows users to switch between sitting and walking modes with ease. A motorized system controls hip and knee joints, while the ankle joint remains flexible to ensure natural motion.

Engineering Meets Human Anatomy

Dr. Ronnapee integrated biomechanics and kinematics compatibility to create a device that mimics natural human movements. The exoskeleton must align with the user’s body to prevent discomfort or strain. A four-bar linkage system was implemented to enhance flexibility, ensuring the device moves in sync with human joints.

Challenges and Future Development

The prototype cost 130,000 baht and was funded by research grants. However, Assoc. Prof. Dr. Ronnapee believes Thailand’s aging population will drive demand for wearable robots. The team is currently developing a second prototype with improved stability for standing and walking. Clinical trials with patients are planned, pending Research Ethics Committee approval. If successful, this Thai-made exoskeleton wheelchair could revolutionize mobility assistance and position Thailand among global leaders in robotics.

For more information, contact ronnapee.c@chula.ac.th.

Read the full article at https://www.chula.ac.th/en/highlight/218151/

Media Contact:
Chula Communication Center
Email: Pataraporn.r@chula.ac.th

HKBU clinches four gold medals at the 15th International Invention Fair in the Middle East

HONG KONG, March 4, 2025 /PRNewswire/ — Hong Kong Baptist University (HKBU) won four gold medals at the 15th International Invention Fair in the Middle East (IIFME) held in Kuwait from 16 to 19 February. It was the first time that HKBU participated in the event.

Four HKBU inventions are awarded gold medals at the 15th International Invention Fair in the Middle East.
Four HKBU inventions are awarded gold medals at the 15th International Invention Fair in the Middle East.

Organised by the Kuwait Science Club under the patronage of His Highness, the Emir of Kuwait, IIFME is one of the largest specialised exhibitions of inventions and innovations in the Middle East. This year the event was organised in collaboration with the International Federation of Inventors’ Associations, the World Intellectual Property Organization, the United Nations Educational, Scientific and Cultural Organization, and the International Exhibition of Inventions of Geneva. The first IIFME was held in 2007 and this edition featured 180 inventors from 42 countries, showcasing a total of 230 inventions.

The four HKBU inventions that have secured gold medals are:

  • Lip-password-based Technology for Identity Verification project by Professor Cheung Yiu-ming, Chair Professor of the Department of Computer Science. The advanced changeable lip password provides secure identity verification based on lip motion, which can resolve the persistent problem of facial recognition in identical twins.
  • M-cell GP2-mediated Lymphatic-targeted Drug Carriers project by Professor Simon Han Quanbin, Professor of the Teaching and Research Division of the School of Chinese Medicine. The project applies a polysaccharide derived from the Chinese herbal medicine Mongolian Milkvetch Root to strengthen oral vaccine efficacy, offering a new treatment protocol for lymphatic diseases. 
  • Thermostable Pigment Nanofiber Coatings for Sustainable and Energy Saving Applications project by Professor Ken Leung Cham-fai, Associate Professor of the Department of Chemistry. This nanofiber technology enhances strength, durability, insulation, waterproofing, and corrosion resistance, reducing maintenance costs and extending structures’ lifespans. 
  • Hydrogen Production from Biomass Waste: Pioneering Advanced Technology for Sustainable Energy Solutions project by Professor Zhao Jun, Associate Professor of the Department of Biology. This technology converts biomass waste with catalysts to high yield green hydrogen in an efficient and environmentally friendly manner.

Aspiring to be a leading research-led university in Asia for the world, HKBU engages in cutting-edge, innovative and transdisciplinary research endeavours that push the boundaries of knowledge, address global issues, and contribute to the well-being of both local and international communities. HKBU’s award winning projects at this year’s IIFME exemplify the university’s unwavering dedication in translating research outcomes into practical applications for the benefit of mankind.

HKBN Survey Reveals Digital Transformation Progress Faced by Social Profit Organisations

80% of Respondents Report Insufficient Digitalisation;
Progress Stalled by Technology Knowledge and Funding Gaps

HONG KONG, March 4, 2025 /PRNewswire/ — Hong Kong Broadband Network Group (“HKBN”) has collaborated with The Social Investment Consultancy (TSIC) to conduct an in-depth survey on the digital transformation journey of ten large social profit organisations (“SPOs”). The survey aimed to identify the current state of digital adoption among SPOs, key challenges, and future needs.

This initiative underscores HKBN’s commitment to empowering the Hong Kong social welfare sector through technology – to enhance operational efficiency, elevate service quality, and remain resilient and responsive in an increasingly digital world.

The survey found that 80% of the SPOs rated their digitalisation at only 60% or below, indicating slow progress in digital transformation. A significant concern is the severe imbalance in IT support, with an average ratio of nearly one IT personnel for every 200 general staff. Furthermore, 60% of the SPOs cited insufficient technological skills among general staff, highlighting a critical shortage of IT talent and challenges in driving digital transformation.

Another major barrier to digital transformation is insufficient funding, with 80% of the SPOs reporting a lack of additional financial resources for digital initiatives. On the other hand, SPOs are eager to digitise administrative processes – such as financial workflows, approvals, and report preparation – to enhance efficiency and attract younger talent. Additionally, SPOs highlighted the need for upgrades to accounting and human resource management systems, including real-time dashboards, analytics, system integration, and e-rostering.

Sally Pang, Assistant Director of Hong Kong Christian Family Service Centre, stated, “SPOs need to manage vast amounts of data on members, volunteers, and event participants, as well as metrics such as service utilisation and event participation rates. Many SPOs aspire to leverage digital technology to optimise resource allocation, reduce administrative costs, and redirect their focus toward serving target audiences. Given that most donations are restricted for specific purposes, we urge the Government or charitable funds to provide more resources and support to help us keep pace with the business sector and achieve digital transformation.”

Jackal Chau, Senior Vice President – Solutions and Service Delivery, HKBN Enterprise Solutions, said, “HKBN Enterprise Solutions is dedicated to supporting SPOs to achieve comprehensive digital transformation through our enterprise resources and technological capabilities. We recognise that SPOs face challenges with staffing and resource constraints, which is why we recommend a phased approach to digitalisation. A practical starting point is financial systems, as most organisational data is ultimately tied to finance. Additionally, in this era of rapid development in artificial intelligence (AI), HKBN can provide a range of best-fit solutions to make AI accessible and affordable for the social welfare sector. By integrating these technologies into their operations, SPOs can significantly enhance efficiency, and streamline data management, allowing them to focus on expanding and improving their services for the communities.”

To promote digital inclusivity, HKBN established the HKBN SPO IT Club in 2023, offering voluntary services such as cybersecurity and IT training.

Interested SPOs can email esg@hkbn.com.hk to register for free consultation services and trial digital solutions. SPOs can also conduct a free online assessment to evaluate their digital readiness at https://bit.ly/hkbnes-digital-transformation.

About HKBN Ltd.

HKBN Ltd. (SEHK Stock Code: 1310, together with its subsidiaries, “HKBN”) is an investment holding company headquartered in Hong Kong, with operations in Hong Kong, Macau and mainland China.  As a leading integrated telecommunications and technology services provider, HKBN offers a comprehensive range of one-stop, high-quality information and communication technology (ICT) solutions, and an unlimited services portfolio. HKBN’s extensive tri-carrier fibre infrastructure covers around 2.6 million residential homes and 8,200 commercial buildings and facilities across Hong Kong.

Committed to creating a lasting positive impact wherever it operates, HKBN received the highest rating of AAA in the MSCI ESG Ratings in 2024. For more information about HKBN, please visit https://www.hkbn.net/group/en.

Village embodies Xi’s philosophy

Editor’s note: China Daily is presenting the series Visionary Pathway to tell the stories of practices and key initiatives promoted by President Xi Jinping during his tenure in various local regions, exploring their transformative impacts and interpreting the consistent values, thoughts and philosophies upheld by the president.

BEIJING, March 4, 2025 /PRNewswire/ — A report from chinadaily.com.cn:

Aojiao, a village at the southeastern tip of Dongshan county, Fujian province, faces the sea on three sides. It is renowned for its 500-year history of maritime culture and beautiful natural scenery, and has become a modern fishing village known for its economic prosperity and ecological preservation. LI JUNTAN/FOR CHINA DAILY
Aojiao, a village at the southeastern tip of Dongshan county, Fujian province, faces the sea on three sides. It is renowned for its 500-year history of maritime culture and beautiful natural scenery, and has become a modern fishing village known for its economic prosperity and ecological preservation. LI JUNTAN/FOR CHINA DAILY

A brisk dawn wind carried a salty tang across Aojiao village as fishing boats glided in with the tide, their cabins loaded with crab, squid tubes and the occasional grouper.

Along the shoreline, 59-year-old fisherman Shen Zhiqun was busy unloading fresh catches with his son, after nights spent navigating the shimmering expanse of the sea.

Shen’s fishing vessel is outfitted with state-of-the-art fishing technologies, and the development of cold chain systems has allowed his catches to reach markets far beyond the coastal village — thanks in part to e-commerce platforms.

However, he said that his 40 years of experience in fishing remained the key to guaranteeing a bumper harvest from each of his fishing trips.

“To me, fishing in the ocean is like going through college. It requires experience, learning from the older generation and taking lessons from the sea,” he said.

Nestled at the southeastern tip of Dongshan county, Aojiao has undergone a dramatic transformation, from a small village to a vibrant fishing community, over the past two decades — a change that captured national attention when President Xi Jinping visited in October last year.

It was Xi’s second trip to the coastal hamlet, and came 23 years after his first visit in 2001, when he served as the province’s governor.

Xi, who is also general secretary of the Communist Party of China Central Committee, praised the village’s evolution over the past 23 years and conveyed an optimistic tone about an even brighter future for rural areas and a more vibrant life for farmers.

The village’s transformation has been widely seen as a validation of Xi’s vision for diversifying the nation’s food supply and broadening the channels of income for rural residents.

Aojiao, dubbed the nation’s most beautiful fishing village, now boasts 88 registered steel-hulled fishing boats and a total of 603 smaller fishing vessels, pushing its annual marine output value past 330 million yuan ($45.3 million) in 2023. Furthermore, the development of aquaculture, e-commerce and rural tourism has broadened the channels of income for village residents, whose average annual disposable income has reached 58,000 yuan.

During his visit last year, Xi fondly recalled that during his first trip to Aojiao in 2001, he already foresaw the village’s enormous potential.

“When I was working in Fujian, I noticed that our island communities held tremendous promise. That’s when I proposed leveraging both the mountains and the sea — using mountain resources if you live by the mountains, and using the sea if you live by the sea,” he said.

Liang Caiyi, an analyst with the Fujian Academy of Social Sciences, noted that Aojiao’s success story has proved correct the long-standing emphasis from Xi that rural areas should tailor their development strategies to local resources.

“A consistent governance philosophy underlies both the president’s vision of leveraging the mountains and the sea and the all-encompassing approach to food,” she said.

Meanwhile, the village’s proper protection of its ocean ecology and environment, and the thriving of rural tourism today, also exemplify the idea that lucid waters and lush mountains are invaluable assets, she added.

Fishermen catch fish at sea in Aojiao village, Dongshan county, Zhangzhou city, East China's Fujian province, Jan 7, 2025. Xu Wei/China Daily
Fishermen catch fish at sea in Aojiao village, Dongshan county, Zhangzhou city, East China’s Fujian province, Jan 7, 2025. Xu Wei/China Daily

Growth drivers

During his tenure in Fujian, Xi championed an all-encompassing approach to food, underscoring the development of under-forest economies — ecologically sustainable activity that relies on forests and woodlands — and marine aquaculture. The approach sought to adapt development strategies to local conditions and fully transform Fujian’s mountains and maritime assets into real drivers of growth.

Shen Ruidong, deputy Party secretary of Aojiao village, said the community has acted on this vision over the past two decades and striven to harness the ocean’s abundance to boost public well-being.

A pivotal moment in the village’s transformation came with the modernization of its fishing fleet, Shen said.

In the early 2000s, fishermen navigated rough waters in small wooden trawlers, and the prospects of deep-sea fishing or aquaculture seemed distant.

Confronted with challenges such as dwindling fish stocks, village officials worked tirelessly to secure bank loans that enabled local fishermen to purchase larger, steel-hulled vessels to replace the wooden trawlers.

These modern vessels — equipped with GPS navigation, hydraulic winches and refrigeration facilities — allow crews to stay at sea for 10 to 15 days at a stretch, venturing farther offshore and significantly cutting costs while boosting profits.

“The refrigeration equipment also allows us to keep the catches fresh and sell at better prices,” he said.

Another key factor that underpinned the village’s prosperity was the gradual pivot to the construction of modern sea farms to bolster the aquacultural sector.

Guo Handong, 57, had to switch from the building of wooden boats to the farming of abalone with the upgrading of the village’s fishing vessels in 2010.

However, a powerful typhoon disrupted his operations years later by causing a power failure, rupturing pipes and causing oxygen levels in the water tanks to plummet — resulting in the loss of nearly half of his stock.

With help from authorities and aquaculture experts, Guo was able to rebuild his farm and deploy modern technology to monitor water quality, manage disease outbreaks, and better protect equipment from severe weather conditions.

Today, Guo’s farm, one of 128 of its kind in Aojiao, boasts 122 tanks — nearly twice its previous capacity — and operates on an internet-of-things system that allows him to regulate oxygen levels with a tap on his phone, producing thousands of abalones each year with a smaller team.

The pivoting from wild catch to aquaculture in Aojiao epitomized the nation’s broader shift in the fishing sector. Nationwide, 82 percent of China’s aquatic products were produced through aquaculture in 2024, with the nation’s aquacultural sector now accounting for nearly 60 percent of global aquaculture output.

Green drive

Environmental restoration has also been central to the village’s renewal, as enhanced measures to treat waste and sewage from aquaculture operations, households and fishing vessels bolstered the local ecology.

Aojiao was once confronted with growing pollution from the quick development of coastal aquaculture, as some farmers erected makeshift structures along the shore, with trash and wastewater discharged directly into the sea, said Shen Ruidong, the village official.

The coastal waters were once teeming with kelp and abalone farms, but foam buoys floated on the surface, and bits of polystyrene littered the beach. During high tide, marine debris would even wash up to residents’ doorsteps.

To tackle these issues, local authorities launched a baywide ecological cleanup, creating no-aquaculture as well as permitted zones, and guiding farmers to designated areas.

They also encouraged upgrading from wooden rafts and foam buoys to eco-friendly plastic net pens and floats, improving the marine environment and restoring orderly offshore operations.

The gradual improvement in ecology and environment has paved the way for the development of rural tourism, allowing Lin Hubin, a military veteran, to set up a homestay while selling seafood on a live­streaming platform.

Lin said the homestay was flooded with bookings during summer and holiday periods, as tourists arrived to experience the seaside lifestyle and fishing practices.

Meanwhile, the improvement in water quality has also significantly improved the quality of produce from aquaculture farms, which pump water from deep in the sea to raise the produce, farmers said.

Cai Yanzhong, head of the bureau of agriculture and rural affairs in Dongshan county, said the trajectory of Aojiao’s development holds key lessons for the rural vitalization of broader regions.

“By leveraging its unique geographical assets and cultivating distinctive local industries, Aojiao has built a diverse economic foundation that includes marine capture and aquaculture, advanced seafood processing, e-commerce and rural tourism,” he said.

“This shows that successful rural vitalization hinges on industry-focused strategies that adapt to local conditions, tap into inherent advantages and develop signature enterprises.”

The village is not without challenges. The dwindling of fish stocks offshore is expected to continue troubling the fishermen, and the aging of the village workforce, with an increasing number of young people migrating to urban areas, is posing obstacles to long-term development, officials said.

Even so, Shen Zhiqun, the fisherman, said he expects that the sea will continue to provide for the village’s future generations.

“Everything we have comes from the sea,” he said. “And as long as we treat it with care and respect, it will continue to give back.”

Taobao Malaysia Celebrates the Festive Period with Its First Raya Sale this March

Celebrate Raya with daily free shipping, exciting deals and cashback giveaways from Taobao

KUALA LUMPUR, Malaysia, March 4, 2025 /PRNewswire/ — Taobao Malaysia is ushering in its first-ever sales campaign dedicated to the Ramadan and Raya season, offering Malaysian shoppers a golden opportunity to discover products that will make this festival truly special. Running throughout March, the month-long campaign features attractive promotions, daily free shipping vouchers, and a carefully curated selection of festive essentials, ensuring that Malaysians can prepare for the celebrations with ease.

Taobao Malaysia Celebrates the Festive Period with  Its First Raya Sale this March
Taobao Malaysia Celebrates the Festive Period with Its First Raya Sale this March

Following the successful introduction of its English interface in September last year, Taobao Malaysia continues its commitment to making the platform more accessible to local users. The Raya campaign is slated to further enhance that experience, providing tailored shopping solutions and promotions that cater to the needs of diverse Malaysian consumers.

Jess Lew, Country Head of Taobao Malaysia, said, “We are thrilled to celebrate one of our country’s biggest festive moments together with our first-ever Raya campaign. We have prepared an abundance of promotions to make it easier and more rewarding for our customers to shop for their festive needs. With the successful implementation of the English interface, we can further enhance the shopping experience, ensuring that everyone can easily access the Taobao platform and shop effortlessly.”

Celebrating the Spirit of Raya with Special Promotions

Shoppers can kickstart their shopping spree on Taobao from 8PM on 3 March with the platform’s promotions. But that’s not all! Taobao has set three amazing promotional phases for different categories packed with thrilling deals to help everyone shop for their Raya essentials.

  • Phase 1: Dapur Syawal Ceria (3 March 8PM – 8 March)

Special promotions on kitchenware such as cooking utensils, baking tools, dining essentials, organisers and storage solutions to help Malaysians prepare their homes for the festive season.

  • Phase 2: Serikan Rumah untuk Raya & Balik Kampung Essentials (9 March – 22 March)

Special discounts on home décor, furniture, lighting, carpets and even travel essentials like suitcases for those heading back to their hometowns.

  • Phase 3: Last Call Raya Sale (23 March – 31 March)

A final chance for shoppers to grab last-minute deals on all must-have Raya essentials before the celebrations begin.

On top of that, shoppers have the chance to grab a limited-time offer, and an RMB35 voucher (equivalent to RM21) to enjoy free shipping with no minimum spend required during this special promotion period.

For first-time Taobao shoppers, there are exciting deals for as low as RMB1 (equivalent to RM0.62) up for grabs, making the Raya campaign the perfect time to join the Taobao community. (Attached link for ¥1 New User Deals: https://intl.taobao.com/sk/01xkbhkBzLC)

Taobao Malaysia is also introducing the “Spend & Win Duit Raya” throughout the campaign to take this Raya promotion to the next level. Shoppers can stand a chance to win up to RMB50 (equivalent to RM30) Duit Raya every Wednesday in March at 12PM (5th, 12th, 19th, 26th) when they make a purchase, with 100 winners per day. The Duit Raya will be in the form of cashback amount, and it will be equivalent to the amount shoppers spend, capped at RMB50 (equivalent to RM30).

“We hope to build a more holistic shopping environment with the promise of delivering our biggest promotion in Malaysia ever. We believe Malaysians will be able to save more and enjoy more this festive season,” concluded Lew.

The Taobao app is available to download for FREE on both the Apple App Store and Google Play. For more details on Taobao Malaysia’s Raya promotion, please stay tuned for updates on the Taobao Malaysia Facebook, Instagram, TikTok and X social media channels or visit the Taobao app.

* The platform rules will prevail over the specific promotion details.

About Taobao Malaysia

Taobao Malaysia aims to facilitate convenient shopping on Taobao and Tmall for consumers in Malaysia. Through the Taobao app, Malaysian shoppers can access billions of products, complete with logistics, payment and other services and offers tailored to their individual market needs. Taobao Malaysia is part of Alibaba International Digital Commerce Group.

Bitget x AB Carnival: Share 235,502,000 $AB Worth $3.5 Million

SINGAPORE, March 4, 2025 /PRNewswire/ — To celebrate the listing of $AB, Bitget (bitget.com) and AB DAO have launched the PoolX & CandyBomb dual airdrop event, rewarding BGB, BTC, ETH holders as well as deposit and trading participants. Tens of thousands of users will have the chance to win a total of 235,502,000 $AB, valued at over $3.5 million.

Event 1: PoolX – Stake BTC, ETH, and BGB to Earn AB Rewards
Total Prize Pool: 165,607,000 AB
Eligible Assets for Staking: BTC, ETH, BGB
Details & Participation: https://x.com/bitgetglobal/status/1896502057533837423 

Event 2: CandyBomb – Deposit & Trade $AB to Earn Airdrop Rewards
Total Prize Pool: 69,895,000 AB
How to Participate: Deposit or trade $AB to qualify for the airdrop
Details & Participation: https://x.com/bitgetglobal/status/1896504574053429395 

Click the links above to participate or share this airdrop event and invite more users to join the AB DAO ecosystem.

Singapore Probes Final Destination of Possible Nvidia Chip Servers

This photo illustration shows the DeepSeek and Nvidia logos on screens in Hangzhou, in China's eastern Zhejiang province, on January 27, 2025. Servers that may contain AI-powering Nvidia chips shipped from the United States to Singapore ended up in Malaysia, but their actual final destination remains a mystery, the city-state's interior minister said on March 3, 2025. (Photo by AFP) / China OUT / CHINA OUT / CHINA OUT
This photo illustration shows the DeepSeek and Nvidia logos on screens in Hangzhou, in China's eastern Zhejiang province, on January 27, 2025. Servers that may contain AI-powering Nvidia chips shipped from the United States to Singapore ended up in Malaysia, but their actual final destination remains a mystery, the city-state's interior minister said on March 3, 2025. (Photo by AFP) / China OUT / CHINA OUT / CHINA OUT

Singapore, Singapore

AFP – Servers that may contain AI-powering Nvidia chips shipped from the United States (US) to Singapore ended up in Malaysia, but their actual final destination remains a mystery, the city-state’s interior minister said Monday.

The US is cracking down on exports of advanced semiconductors to China, seeking to retain a competitive edge over the technology. 

But Bloomberg News reported in late January that US officials were probing whether DeepSeek bought advanced Nvidia semiconductors through third parties in Singapore, skirting Washington’s restrictions.

Shanmugam, who is also the law minister, said the route of the chips emerged in the course of an investigation of three men charged last week with fraud by making false representations.

Local media have linked their cases to the alleged movement of Nvidia chips from Singapore to be used by Chinese AI firm DeepSeek.

“Essentially, the case relates to servers with chips embedded in them coming into Singapore, and then from Singapore, they went to Malaysia,” Shanmugam said.

The servers were supplied to Singapore-based companies by US firms Dell and Super Micro, according to Shanmugam.

“The question is whether Malaysia was a final destination or from Malaysia it went to somewhere else, which we do not know for certain at this point,” he said. “But we assessed that there may have been false representation on the final destination of the servers.”

He said Singapore had asked both the US and Malaysia for more information.

Pressed about links to Nvidia, Shanmugam said, “We assessed that the servers may contain Nvidia chips. I think that’s the highest I can put it at, at this point.”

In January, DeepSeek released its R1 chatbot, shaking the global tech market and claiming its tool can match the capacity of top US AI products for a fraction of their costs.

© Agence France-Presse